MANILA, Philippines – The Food and Drug Administration (FDA) will release next week the list of “fake” vinegar products with synthetic acetic acid.
FDA officer-in-charge Eric Domingo said they are still testing vinegar brands suspected to be produced not from natural fermentation and biogenic ingredients but from synthetic acetic acid.
The FDA made the announcement following the call of the Department of Agriculture (DA) to release the list of the alleged fake vinegar products available in the market to ensure the safety of consumers.
A study conducted by the Philippine Nuclear Research Institute-Department of Science and Technology (PNRI-DOST) found that eight out of 10 vinegar products in the market are made from synthetic acetic acid and not from natural sources.
The research team explained that vinegar and other condiments from natural or plant-based sources are safer than those derived from petroleum-based sources.
“One can only imagine all the impurities and residues from the petroleum by-products, which can be the source of various degenerative diseases,” said Raymond Sucgang, section head of the PNRI Nuclear Analytical Techniques Applications Section.
The PNRI did not mention the brand names of the products used in the test but it assured that the results of the vinegar studies have already been submitted to the FDA.
Earlier, the DA advised consumers to exercise caution and discernment in buying vinegar from commercial establishments. The department also recommends that consumers buy natural vinegar made out of coconut sap and water, sugarcane, nipa and fruits which are readily available in the market.
For its part, the Department of Health (DOH) said once the PNRI study has been validated by the FDA, they will order the pull out of vinegar brands proven synthetic from local markets.
At present, there are a total of 274 vinegar brands duly registered by the FDA.
MANILA, Philippines – The country’s Food and Drug Administration (FDA) on Friday said the approval of a vaccine against novel coronavirus disease may be possible in April 2021.
During a virtual press briefing, FDA Director General Eric Domingo said this is “the best case scenario” if clinical trials are completed on schedule.
“If clinical trials are completed by December or January, and a company would file an application with FDA, it’s possible that by April 2021 we will have an approved vaccine,” he said.
“Talagang best case scenario yun, meaning yung three to six months, magiging three months; assuming that they will complete all their analysis and submitted immediately to FDA,” he added.
In the same briefing, Department of Science and Technology (DOST) Secretary Fortunato dela Peña said the time period of three to six months is the experts’ estimate on the completion of Phase III clinical trials for vaccine candidates.
“When they say 3-6 months, we prefer to use the longer forecast in our estimates. That would indicate in that period they would have finished clinical trials and probably already submitted to FDA their application and results of their trials,” he said.
Dela Peña said the World Health Organization (WHO) is set to release its list of selected vaccines and protocols in October and that the fastest that they can start the clinical trials will be in the last quarter of 2020.
“The vaccine trials according to experts will range from 3 to 6 months. I think the very early forecast that we have of second quarter 2021 is still the best forecast we can give,” he said.
The DOST said the Philippines is currently negotiating with 17 vaccine developers from other countries and six of them have already signed confidentiality disclosure agreements that would allow the sharing of their earlier trial results.
Among the six vaccine developers are Russia’s Gamaleya Research Institute and China’s Sinovac.
The FDA earlier promised it would expedite the approval procedures but assured that no steps will be skipped to ensure public’s health and safety. – RRD (with details from Correspondent Aiko Miguel)
The Food and Drug Administration (FDA) has clarified that the traditional Chinese medicine, Lian Hua Qin Weng, is not registered in the Philippines as a product for coronavirus disease (COVID-19).
Although Lian Hua Qin Weng is used as a COVID-19 treatment in China and other countries, it is not registered for the same purpose in the Philippines, according to FDA Director General Eric Domingo.
“Dito sa Pilipinas approved natin siya as traditional-use herbal product (Here in the Philippines, it is approved as traditional-use herbal product) that helps remove toxins, invasion of the lungs including symptoms such as fever, cold, muscle soreness, stuffy and runny nose. Kasi iyong mga traditional medicines ang tini-treat niyan symptoms, alleviate symptoms. Hindi talaga siya directed to one particular illness, (Because these traditional medicines treat or alleviate symptoms. It is not really directed to one particular illness),” he said.
On Wednesday (August 12), the Chinese Embassy released a statement describing Lian Hua Qin Weng as a treatment for moderate and mild cases of COVID-19 in China.
However, in the Philippines, Domingo said the medicine still needs to undergo clinical trials and cannot be labeled as a treatment for COVID-19.
“Dito sa atin ang traditional medicine hindi natin siya ina-approve for particular illnesses […] hindi siya pwedeng i-label sa atin as treatment for COVID-19. Hindi siya pwedeng ibenta as that dito sa Pilipinas, (Here, traditional medicine is not approved for particular illnesses […] we cannot label it as treatment for COVID-19. It cannot be sold here in the Philippines as such),” he added.
The FDA official also explained that the medicine is a prescription drug and will not be sold over-the-counter. The FDA also warned the public not to buy Lian Hua Qin Weng online.
“Kailangan magpatingin sa doctor. Mag-reseta at pwede lang siyang ibenta sa mga licensed pharmacies or licensed retail outlets, (One needs to consult a doctor. A prescription is needed and the medicine can only be sold at licensed pharmacies or licensed retail outlets)” Domingo said. AAC (with reports from Aiko Miguel)
MANILA, Philippines — The Food and Drug Administration (FDA) has approved a traditional Chinese drug for the treatment of mild coronavirus disease 2019 (COVID-19).
According to the Certificate of Product Registration released by the FDA, Lian Hua Qing Wen “has been found to conform with the requirements and standards for marketing authorization for pharmaceutical products per existing regulations in force as of date hereof.”
Lian Hua Qing Wen, produced by traditional Chinese medicine manufacturer Shijiazhuang Yiling Pharmaceutical Co. Ltd., was approved for use in the Philippines last Friday (August 7).
In a statement, the Chinese Embassy in the Philippines said the approval was a welcome development for them as “this marks an important progress in the entry of TCM products into the Philippine market.”
The statement added that the said medicine is an approved COVID-19 treatment for mild and moderate cases in China.
The embassy added that the drug has also been approved in Hong Kong, Macau, Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, and Laos.
“It is our sincere hope that its entrance into the Philippine market will contribute to the fight against the spread of COVID-19 in this country and help the patients with mild and moderate symptoms recover,” it added.
The embassy, however, advised consumers to purchase and consume authentic traditional Chinese medicine only.
The Embassy also hopes that “TCM would play a bigger role to support the efforts of the Philippine government and its people to fight against COVID-19 until the final victory.” — /mbmf
UNTV is a major TV broadcast network with 24-hour programming. An Ultra High Frequency station with strong brand content that appeal to everyone, UNTV is one of the most trusted and successful Philippine networks that guarantees wholesome and quality viewing experience.